NCT05168800

CONFIDENT: Supporting Long-term Care Workers During COVID-19

Completed NA Results posted Last updated 5 August 2025

What this trial tests

NA trial testing Dialogue-Based Webinar in COVID-19 in 2,634 participants. Completed in 20 September 2023.

Timeline

21 February 2022

Primary endpoint
20 February 2023

20 September 2023

Quick facts

Lead sponsor	Dartmouth-Hitchcock Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	other
Enrollment	2,634
Start date	21 February 2022
Primary completion	20 February 2023
Estimated completion	20 September 2023
Sites	1 location across United States

Drugs / interventions tested

• Dialogue-Based Webinar
• Social Media Website
• Enhanced Usual Practice

Conditions studied

• COVID-19 — all drugs for COVID-19 →

Sponsor

Dartmouth-Hitchcock Medical Center

Who can join

18 and older, any sex, with COVID-19. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

COVID-19 Vaccine Confidence Primary · 3 weeks post-randomization (Time 1)

Confidence in the COVID-19 vaccines, assessed using the 3-item Vaccine Confidence Index (Larson et al., 2016) adapted for COVID-19. Each item is rated on a 5-point scale ranging from 1 ('Strongly disagree') to 5 ('Strongly agree'). Respondents are considered 'confident' (score of '1') if they respond 'Agree' or 'Strongly agree' on all three items and 'not confident' (score of '0') if one or more item responses is not 'Agree' or 'Strongly agree'.

Group	Value	95% CI
Dialogue-Based Webinar	93
Social Media Website	106
Enhanced Usual Practice	138

Change From Baseline to 3 Weeks Post-randomization in COVID-19 Vaccine Confidence Secondary · Baseline (Time 0); 3 weeks post-randomization (Time 1)

Change in confidence in the COVID-19 vaccines from baseline to 3 weeks post-randomization, assessed using the 3-item Vaccine Confidence Index (Larson et al., 2016) adapted for COVID-19. Each item is rated on a 5-point scale ranging from 1 ('Strongly disagree') to 5 ('Strongly agree'). Respondents are considered 'confident' (score of '1') if they respond 'Agree' or 'Strongly agree' on all three items and 'not confident' (score of '0') if one or more item responses is not 'Agree' or 'Strongly agree'. For the change from baseline to Time 1 outcome, a score of 1 represents an increase in vaccine c

Group	Value	95% CI
Dialogue-Based Webinar	42
Social Media Website	49
Enhanced Usual Practice	62

Change From Baseline to 3 Months Post-randomization in COVID-19 Vaccine Confidence Secondary · Baseline (Time 0); 3 months post-randomization (Time 2)

Change in confidence in the COVID-19 vaccines from baseline to 3 months post-randomization, assessed using the 3-item Vaccine Confidence Index (Larson et al., 2016) adapted for COVID-19. Each item is rated on a 5-point scale ranging from 1 ('Strongly disagree') to 5 ('Strongly agree'). Respondents are considered 'confident' (score of '1') if they respond 'Agree' or 'Strongly agree' on all three items and 'not confident' (score of '0') if one or more item responses is not 'Agree' or 'Strongly agree'. For the change from baseline to Time 2 outcome, a score of 1 represents an increase in vaccine

Group	Value	95% CI
Dialogue-Based Webinar	57
Social Media Website	58
Enhanced Usual Practice	55

Change From Baseline to 6 Months Post-randomization in COVID-19 Vaccine Confidence Secondary · Baseline (Time 0); 6 months post-randomization (Time 3)

Change in confidence in the COVID-19 vaccines from baseline to 6 months post-randomization, assessed using the 3-item Vaccine Confidence Index (Larson et al., 2016) adapted for COVID-19. Each item is rated on a 5-point scale ranging from 1 ('Strongly disagree') to 5 ('Strongly agree'). Respondents are considered 'confident' (score of '1') if they respond 'Agree' or 'Strongly agree' on all three items and 'not confident' (score of '0') if one or more item responses is not 'Agree' or 'Strongly agree'. For the change from baseline to Time 3 outcome, a score of 1 represents an increase in vaccine

Group	Value	95% CI
Dialogue-Based Webinar	52
Social Media Website	66
Enhanced Usual Practice	62

Net Promoter Score (COVID-19 Vaccination) Secondary · 3 weeks post-randomization (Time 1)

Likelihood of recommending COVID-19 vaccination to someone who is not vaccinated, assessed using a single-item adapted Net Promoter Score item. The item is assessed on an 11-point scale ranging from 0 ('No at all likely') to 10 ('Extremely likely'). Responses are categorized into three groups: Promoters (scale score of 9 or 10) receive a score of '1', passives (scale score of 7 or 8) receive a score of '0', and detractors (scale score of 0-6) receive a score of '-1'.

Group	Value	95% CI
Dialogue-Based Webinar	-0.48	± 0.04
Social Media Website	-0.52	± 0.03
Enhanced Usual Practice	-0.42	± 0.04

Net Promoter Score (COVID-19 Booster Vaccination to Coworker) Secondary · 3 weeks post-randomization (Time 1)

Likelihood of recommending COVID-19 booster vaccination to a coworker, assessed using a single-item adapted Net Promoter Score item. The item is assessed on an 11-point scale ranging from 0 ('No at all likely') to 10 ('Extremely likely'). Responses are categorized into three groups: Promoters (scale score of 9 or 10) receive a score of '1', passives (scale score of 7 or 8) receive a score of '0', and detractors (scale score of 0-6) receive a score of '-1'.

Group	Value	95% CI
Dialogue-Based Webinar	-0.59	± 0.09
Social Media Website	-0.62	± 0.04
Enhanced Usual Practice	-0.51	± 0.04

COVID-19 Vaccine Uptake (Any Dose) Secondary · 3 weeks post-randomization (Time 1)

Receipt of any does of a COVID-19 vaccine, assessed using a single item with multiple choice (single answer) format.

Group	Value	95% CI
Dialogue-Based Webinar	363
Social Media Website	383
Enhanced Usual Practice	397

COVID-19 Vaccine Uptake (Initial Series Completion) Secondary · 3 weeks post-randomization (Time 1)

Completion of initial COVID-19 vaccine series, assessed using two items with multiple choice (single answer) formats.

Group	Value	95% CI
Dialogue-Based Webinar	354
Social Media Website	374
Enhanced Usual Practice	391

COVID-19 Vaccine Uptake (Booster Completion) Secondary · 3 weeks post-randomization (Time 1)

Receipt of a COVID-19 booster vaccine if initial series completed, assessed using a single item with multiple choice (single answer) format.

Group	Value	95% CI
Dialogue-Based Webinar	132
Social Media Website	144
Enhanced Usual Practice	145

COVID-19 Vaccine Intent (Initial Series) Secondary · 3 weeks post-randomization (Time 1)

Intent to get a COVID-19 vaccine if unvaccinated, assessed using a single item with multiple choice (single answer) format. Response options are Yes (score of '1'), Not Sure (score of '0'), and No (score of '-1').

Group	Value	95% CI
Dialogue-Based Webinar	-0.76	± 0.07
Social Media Website	-0.77	± 0.05
Enhanced Usual Practice	-0.62	± 0.06

COVID-19 Vaccine Intent (Booster) Secondary · 3 weeks post-randomization (Time 1)

Intent to get a COVID-19 booster vaccine if not yet received, assessed using a single item with multiple choice (single answer) format. Response options are Yes (score of '1'), Not Sure (score of '0'), and No (score of '-1').

Group	Value	95% CI
Dialogue-Based Webinar	-0.26	± 0.05
Social Media Website	-0.16	± 0.05
Enhanced Usual Practice	-0.17	± 0.05

COVID-19 Vaccine Intent (Future Vaccine Recommendations) Secondary · 3 weeks post-randomization (Time 1)

Intent to get COVID-19 vaccines regularly in the future if they are recommended, assessed using a single item with multiple choice (single answer) format. Response options are Yes (score of '1'), Not Sure (score of '0'), and No (score of '-1').

Group	Value	95% CI
Dialogue-Based Webinar	-0.16	± 0.04
Social Media Website	-0.17	± 0.04
Enhanced Usual Practice	-0.09	± 0.04

Sponsor's own description

The CONFIDENT Study is an online three-arm randomized trial that aims to help long-term care workers in the United States feel more confident about the Coronavirus Disease 2019 (COVID-19) vaccines. The study will compare two different interventions to usual online information (website of the Centers for Disease Control and Prevention). The first intervention is a Dialogue-Based Webinar where people can interact and ask questions about the vaccines. The second intervention is a Social Media Website that will feature curated content about the vaccines from popular social media platforms.

Participants will be asked to completed four online surveys. The first survey will be completed pre-intervention and immediately upon study enrollment (Time 0). Participants will be randomized to a trial arm at the end of the Time 0 survey. Intervention follow-up surveys will be completed 3 weeks post-randomization (Time 1), three months post-randomization (Time 2), and 6 months post-randomization (Time 3).

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. Co-Development of a Web Application (COVID-19 Social Site) for Long-Term Care Workers ("Something for Us"): User-Centered Design and Participatory Research Study.
   Saunders CH, Sierpe A, Stevens G, Elwyn G, et al · · 2022 · cited 7× · PMID 35926074 · DOI 10.2196/38359
2. The effects of long COVID-19, its severity, and the need for immediate attention: Analysis of clinical trials and Twitter data.
   Bhattacharyya A, Seth A, Rai S. · · 2022 · cited 4× · PMID 36588926 · DOI 10.3389/fdata.2022.1051386
3. The CONFIDENT study protocol: a randomized controlled trial comparing two methods to increase long-term care worker confidence in the COVID-19 vaccines.
   Stevens G, Johnson LC, Saunders CH, Schmidt P, et al · · 2023 · cited 2× · PMID 36823559 · DOI 10.1186/s12889-023-15266-x
4. The Effects of Long COVID-19, its Severity, and the Need for Immediate Attention: Analysis of Clinical Trials and Twitter data
   Bhattacharyya A, Seth A, Rai S. · · 2022 · DOI 10.1101/2022.09.13.22279833